Atreides Management LP Sells 50,446 Shares of Bath & Body Works, Inc. $BBWI

Key Points

• Atreides Management LP reduced its stake in Bath & Body Works by 14.5%, owning 298,000 shares worth approximately $9 million after selling over 50,000 shares in the first quarter.
• Analysts have mixed views on Bath & Body Works, with targets ranging from $32 to $46, and a consensus rating of "Moderate Buy" based on recent research notes.
• The company announced a quarterly dividend of $0.20 per share, reflecting an annual yield of 2.7%, with a payout ratio of approximately 24%.

Atreides Management LP reduced its holdings in shares of Bath & Body Works, Inc. (NYSE:BBWI - Free Report) by 14.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 298,000 shares of the company's stock after selling 50,446 shares during the period. Atreides Management LP owned 0.14% of Bath & Body Works worth $9,035,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of BBWI. SVB Wealth LLC purchased a new position in Bath & Body Works during the 1st quarter valued at about $35,000. Golden State Wealth Management LLC lifted its position in Bath & Body Works by 94.7% during the 1st quarter. Golden State Wealth Management LLC now owns 1,320 shares of the company's stock valued at $40,000 after acquiring an additional 642 shares during the period. UMB Bank n.a. lifted its position in Bath & Body Works by 65.9% during the 1st quarter. UMB Bank n.a. now owns 1,501 shares of the company's stock valued at $46,000 after acquiring an additional 596 shares during the period. Ancora Advisors LLC purchased a new position in Bath & Body Works during the 4th quarter valued at about $67,000. Finally, GKV Capital Management Co. Inc. purchased a new position in Bath & Body Works during the 1st quarter valued at about $69,000. 95.14% of the stock is owned by hedge funds and other institutional investors.

Bath & Body Works Stock Performance

Shares of BBWI traded down $2.38 during mid-day trading on Friday, hitting $29.49. 10,016,218 shares of the company traded hands, compared to its average volume of 6,016,592. The stock has a 50-day moving average price of $30.73 and a two-hundred day moving average price of $30.45. Bath & Body Works, Inc. has a 1 year low of $24.94 and a 1 year high of $41.87. The stock has a market cap of $6.08 billion, a price-to-earnings ratio of 8.75, a P/E/G ratio of 1.01 and a beta of 1.49.

Bath & Body Works (NYSE:BBWI - Get Free Report) last released its quarterly earnings data on Thursday, August 28th. The company reported $0.37 earnings per share for the quarter, meeting the consensus estimate of $0.37. Bath & Body Works had a net margin of 9.88% and a negative return on equity of 48.43%. The firm had revenue of $1.55 billion during the quarter, compared to analysts' expectations of $1.55 billion. During the same period in the previous year, the company earned $0.37 earnings per share. The firm's quarterly revenue was down .8% on a year-over-year basis. Bath & Body Works has set its Q3 2025 guidance at 0.370-0.45 EPS. FY 2025 guidance at 3.350-3.600 EPS. On average, analysts forecast that Bath & Body Works, Inc. will post 3.3 EPS for the current year.

Bath & Body Works Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 5th. Investors of record on Friday, August 22nd were given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 2.7%. The ex-dividend date was Friday, August 22nd. Bath & Body Works's payout ratio is 23.74%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on BBWI shares. The Goldman Sachs Group decreased their target price on shares of Bath & Body Works from $44.00 to $43.00 and set a "buy" rating for the company in a report on Friday, May 30th. Wells Fargo & Company lifted their target price on shares of Bath & Body Works from $40.00 to $44.00 and gave the stock an "overweight" rating in a report on Wednesday, May 14th. Wall Street Zen cut shares of Bath & Body Works from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. JPMorgan Chase & Co. lifted their target price on shares of Bath & Body Works from $40.00 to $46.00 and gave the stock an "overweight" rating in a report on Monday, July 28th. Finally, UBS Group decreased their target price on shares of Bath & Body Works from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday, August 29th. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $41.62.

Bath & Body Works Company Profile

Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.